Repurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/0 Comments/in Drug repurposing, Preclinical Research/by MaxTags
abiraterone acetate ADT ai in healthcare alphafold AMG 509 androgen deprivation therapy antibody-drug conjugate apalutamide ARANOTE artificial intelligence bispecific antibody CAN-2409 cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology personalized medicine preclinical prostate cancer PSA response PSMA radioligand therapy radiopharmaceuticals real-world data small molecule STEAP1 T-cell therapy theranostics
Latest Posts
- Harnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer January 15, 2025
- VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025
- Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer January 14, 2025
- RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy January 14, 2025